Direct answer
CJC-1295 is a synthetic GHRH analog; Ipamorelin is a selective growth hormone secretagogue. Online culture sells the pair as a GH-axis "stack." Honest readout: published human data largely describe each ingredient separately (and for CJC-1295, mainly the with-DAC form); a strong peer-reviewed package proving everyday body-composition, recovery, or anti-aging claims for the combination is missing; and there is no FDA-approved CJC-1295 + Ipamorelin finished drug for those uses. Synergy talk is not combination trial proof — and neither peptide is somatropin.
What it is
CJC-1295 stimulates pituitary GH release via GHRH pathways. Literature often splits two related forms:
| Form | What it generally means | Evidence caution |
|---|---|---|
| With DAC (Drug Affinity Complex) | Albumin-binding linker; longer half-life; form in the main healthy-adult trials | Do not paste those results onto "no-DAC" products |
| Without DAC (Modified GRF 1-29 / Mod-GRF) | Shorter-acting analog without the DAC linker | Lacks the same published human package; do not invent equivalence |
Ipamorelin is a selective GH secretagogue with relatively little ACTH/cortisol signal versus older GHRPs in animal characterization. Human efficacy data are sparse; a Phase 2 postoperative-ileus study did not meet its primary endpoint — not a gym "recomp" win.
What the stack is not: an FDA-approved medicine; brand-equivalent to somatropin; proof that two GH-axis peptides equal approved GH therapy; or a DIY recipe. This page invents no dosing, units, or injection schedules.
What's in the vial vs an approved product
| Feature | Typical CJC / Ipamorelin vial or "stack" prep | FDA-approved GH product (e.g., somatropin) |
|---|---|---|
| Status | Compounded prep, RUO labeling, or unapproved marketing | NDA/BLA pathway; labeled indications |
| Quality | Variable identity (DAC vs no-DAC), purity, sterility | Lot controls; pharmacovigilance |
| Evidence | Ingredient studies ≠ stack RCTs for "optimization" | Substantial evidence for labeled uses |
| Sameness | Not somatropin or other approved GH products | Recombinant GH with labeled indications |
| Scoreboard | We do not source or recommend research-only products sold for human use. | Clinician-supervised, legitimate pathways only |
FDA has flagged peptide impurity/immunogenicity concerns and listed safety-risk language for CJC-1295 (heart-rate and vasodilatory reaction reports; limited clinical data) and Ipamorelin acetate (immunogenicity concerns; serious AEs including death noted in an IV gastric-motility study context — causality not fully settled). Nomination history and advisory votes do not equal FDA drug approval. RUO peptides sold with lifestyle claims are the highest-risk channel for purity, sterility, and dose chaos.
Proven vs unproven
| Claim area | More honest / evidence-aligned | Unproven / overclaimed |
|---|---|---|
| Molecules | GHRH analog + selective secretagogue | "Natural GH therapy in a vial" |
| CJC-1295 with DAC | Healthy-adult trials (Teichman et al., JCEM 2006) showed multi-day GH/IGF-I rises | Those results apply to every online "CJC" label |
| CJC-1295 without DAC | Short-acting GHRH-analog relative | Same published package as with-DAC |
| Ipamorelin alone | Selective GH-release characterization (Raun 1998); limited clinical efficacy | Proven fat-loss / muscle / sleep drug |
| The stack | Dual-receptor rationale is a hypothesis; stack evidence ≠ single-ingredient evidence | Combination RCTs prove "recomp" or anti-aging |
| vs somatropin | Different modality and labels | "Same as HGH / Genotropin / Norditropin" |
| Sport | GH-releasing factors / secretagogues generally prohibited | "Research peptide, so athletes are fine" |
If a strong published human RCT for the claimed stack use does not exist: unproven for that use in humans.
Benefits (honest)
- Scientific interest is real — Clear pituitary pharmacology. Interest ≠ approved "optimization" therapy.
- Men ask for a reason — Recovery, body composition, and sleep dominate search. Curiosity ≠ certainty.
- Ingredient data ≠ stack proof — Signals for one CJC form or Ipamorelin alone do not finish a blend package.
- Evaluation beats a vial — Sleep, training, nutrition, and indicated labs often explain the symptom better than a peptide nickname.
Skipping RUO products means fewer sterility unknowns and fewer anti-doping landmines.
Risks / side-effect table
| Risk domain | What men should understand | Note |
|---|---|---|
| Unapproved status | No FDA-approved finished stack for optimization uses | Not an approved therapeutic |
| Compounding / RUO | 503A/503B pathways ≠ influencer charts; gray-market RUO risks purity/sterility chaos | Advisory votes ≠ drug approval |
| Immunogenicity & impurities | Peptide impurity/immune concerns for some routes | FDA bulk-substance safety-risk language |
| Cardiac / systemic | CJC-1295: heart-rate and vasodilatory reaction reports; limited data | Missing long-term safety database is a risk |
| Ipamorelin clinical gaps | Serious AEs (including death) flagged in FDA discussion of an IV motility study | Caution, not a green light |
| Metabolic / IGF-I | GH-axis stimulation is not risk-free | Do not assume "secretagogue = safer than GH" |
| Anti-doping / false equivalence | Generally prohibited for tested athletes; not somatropin | WADA/USADA; delayed real evaluation |
We do not source or recommend research-only products sold for human use.
This is not a DIY dosing guide — no microgram schedules, reconstitution recipes, or injection instructions appear here.
Who may discuss / who should avoid
May discuss with a licensed clinician
- Men who want an evidence-first talk on GH-axis peptide claims
- Patients already in clinician-guided pathways who need a reality check on "stack" marketing
- Athletes who must confirm WADA/USADA status
- Anyone considering peptides without labs, meds review, and goal clarification
Should avoid self-directed experiments
- Competitive/tested athletes
- Men with active malignancy concerns or unfinished oncology workups
- People with uncontrolled diabetes, significant cardiovascular disease, or untreated pituitary disease without oversight
- Anyone shopping "research only" vials
- Anyone expecting guaranteed muscle, fat-loss, or anti-aging timelines
Scoreboard Health is education-first and clinician-guided. Scoreboard does not currently offer CJC-1295, Ipamorelin, or this stack; this page is education only. Soft links below support general evaluation pathways only — not a way to obtain this stack.
Comparison to branded / approved GH options (no sameness)
There is no FDA-approved CJC-1295 + Ipamorelin finished drug for the uses marketed online. Do not treat it as brand-equivalent to somatropin or other approved GH products.
| Approach | What it generally is | Education pointer |
|---|---|---|
| FDA-approved somatropin (e.g., Genotropin, Norditropin, Omnitrope) | Recombinant GH with labeled indications | Different class and package — not this stack |
| FDA-approved GHRH analog (tesamorelin / Egrifta) | Labeled for specific HIV lipodystrophy use | Not a gym "CJC substitute" |
| Compounded CJC and/or Ipamorelin (if under finished FDA compounding rules) | Pharmacy-prepared — not an approved finished drug | Compounding ≠ approval; DAC vs no-DAC matters |
| RUO / research-chem vials | Lab-labeled materials diverted to humans | We do not source or recommend research-only products sold for human use. |
| Peptide "stacks" | Multi-ingredient protocols sold as synergy (e.g., with BPC-157) | Ingredient evidence ≠ combination evidence |
"Men hear 'CJC + Ipamorelin' and assume it is a softer version of growth hormone. It is not. Single-ingredient papers — especially CJC-1295 with DAC — do not automatically prove the stack, and none of this equals FDA-approved somatropin. Research-only vials sold for human use are a separate high-risk category we refuse to normalize."
FAQs
1. Is the CJC-1295 + Ipamorelin stack FDA-approved?
No. No FDA-approved finished drug of this combination exists for muscle, recovery, fat-loss, or anti-aging uses as of September 2026.
2. Does a single-ingredient study prove the stack works?
No. Stack evidence ≠ single-ingredient evidence. Synergy talk is not a substitute for combination trials.
3. Is CJC-1295 with DAC the same as without DAC?
No. With-DAC literature (including the main healthy-adult JCEM work) should not be pasted onto no-DAC / Modified GRF products.
4. Is this the same as HGH / somatropin?
No. Do not claim sameness to Genotropin, Norditropin, Omnitrope, or other labeled somatropin products.
5. What about research-use-only CJC or Ipamorelin online?
RUO labeling does not make human injection safe or appropriate. We do not source or recommend research-only products sold for human use.
6. Can I dose it from a forum chart?
No DIY dosing, units, reconstitution, or injection schedules appear here. Ask a licensed clinician.
7. Is "compounded" the same as "FDA-approved"?
No. An approved drug has completed FDA's drug-approval process for a labeled use; compounding is a separate pathway.
8. Are these peptides banned in sport?
GH-releasing factors and related secretagogues are generally prohibited for WADA-tested athletes. Confirm current WADA/USADA status.
9. What did Ipamorelin's human efficacy trial show?
A Phase 2 postoperative-ileus study did not meet its primary endpoint — not proof of gym or anti-aging benefit.
10. How does Scoreboard approach stack questions?
Scoreboard does not currently offer CJC-1295, Ipamorelin, or this stack; this page is education only. Education first and a hard line against research-only products sold for human use. Soft links to How it works / Treatments are general evaluation pathways — not a stack request. See /how-it-works and /treatments.
Bottom line + So what?
Bottom line: CJC-1295 and Ipamorelin are often paired as a GH-axis stack, but they are not FDA-approved finished drugs for optimization uses. Distinguish with-DAC vs without-DAC when reading papers; do not equate ingredient signals with combination proof; and do not treat the stack as somatropin.
So what? Get a real evaluation — history, labs when indicated, sleep/training/nutrition context, meds review, and anti-doping reality if you compete. We do not source or recommend research-only products sold for human use.
Scoreboard does not currently offer CJC-1295, Ipamorelin, or this stack; this page is education only.
Soft next steps are for general men's health evaluation pathways — not a way to "get" CJC-1295, Ipamorelin, or this stack.
To learn how Scoreboard structures clinician-guided evaluation and monitoring, see: How it works · Treatments (current catalog offerings — this stack is not offered)
Related reading
Disclaimer: This content is for education only — not medical advice, diagnosis, or a substitute for licensed care. Do not start, stop, or change any medication, peptide, or injectable based on a blog post. Scoreboard Health does not provide DIY dosing or research-chemical sourcing advice. We do not source or recommend research-only products sold for human use.
Reviewed by: Ariel Bowerman, BSN, R.N. (education support; not a prescribing clinician) · Last evidence check: September 2026
Sources
- U.S. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. fda.gov
- U.S. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov
- Teichman SL et al. Prolonged stimulation of GH and IGF-I by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006. PubMed
- Ionescu M, Frohman LA. Pulsatile GH persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006. PubMed
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed
- Beck DE et al. Ipamorelin for postoperative ileus. Int J Colorectal Dis. 2014. PubMed
- World Anti-Doping Agency. The Prohibited List. wada-ama.org
- U.S. FDA. GENOTROPIN (somatropin) labeling (approved GH example — not this stack). fda.gov
Learn how Scoreboard Health structures men's evaluation pathways: How it works · Treatments